Johnson & Johnson (JNJ)
Health Care · Pharmaceuticals · US stock · S&P 500 component
$255.56
▲ +2.28 (0.90%)
Fair valueFair
$214 −16.1% to fair value
$107fair band $150–$279$322
Day's range
$254.00 – $257.55
52-week range
$180.59 – $281.07
About Johnson & Johnson
Johnson & Johnson is a health care company focused on innovative medicines and medical technology. Its pharmaceutical business develops drugs for areas such as cancer, immunology and neuroscience, while its medtech business sells surgical, orthopaedic, cardiovascular and vision products. Revenue comes from sales to hospitals, pharmacies and wholesalers, and results depend on patent life, regulatory decisions and legal matters such as product claims.
The company reported trailing revenue of $97.9 billion and three-year growth of 5.6% a year. Profitability figures show an operating margin of 26.8% and a return on invested capital of 19%. Its net debt to EBITDA ratio stands at 0.8 times. The dividend yield is 2.1%. Its X-Ray Score is 50 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $180.59 – $281.07Volume 6,548,000Daily, split-adjusted
Vitals
Market cap$623.6B
52-week range$180.59 – $281.07
Volume (last day)6,548,000
P/E (TTM)29.6
EBIT / EV yield4.0%
Free-cash-flow yield3.6%
Dividend yield2.1%
Revenue (TTM)$97.9B
Net income (TTM)$21.0B
Operating margin26.8%
Return on capital19.3%
Debt incl. leases$49.0B
Cash & securities$20.8B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$214model spread $206 – $224
Fair
−16.1% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $256
Undervalued < $150Fair $150 – $279Overvalued > $279
10-year DCF (market-scaled)
$190
Peer multiples
$233
Earnings power floor (not blended)
$81
Fundamentals-adjusted multiple
$220
Growth the price implies
16.5%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
44/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield4.0%
Free-cash-flow yield3.6%
Fair value vs price0.8×
Growth
Fair
58/100
Growing at a typical pace for its sector.
See the numbers →
Revenue growth (3y)5.6%
EPS growth (3y)17.9%
Growth consistency100%
Profitability
Fair
57/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital19.3%
Operating margin26.8%
Gross profitability33.1%
Financial health
Weak
48/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score4 / 9
Net debt / EBITDA0.8×
Interest cover25.9×
Dividends
Weak
42/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield2.1%
Dividends vs free cash flow58%
Dividend growth2.0%
Quarterly results: last 6 quarters
+2.4%
Mar '25
+5.8%
Jun '25
+6.8%
Sep '25
+9.1%
Dec '25
+9.9%
Mar '26
+6.6%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $25.3B, diluted EPS $2.27.
Compare with peers
ZTS Zoetis Inc.68 LLY ELI LILLY & Co61 BMY Bristol Myers Squibb C...59 MRK Merck & Co., Inc.32Other Pharmaceuticals companies by X-Ray Score.
Fundamentals checklist
● 6 Good · ● 8 Average · ● 2 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldAverage
Risk models
Altman Z''Good
Piotroski F-ScoreBad
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Average
Revenue growth (3y)Average
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDAGood
Interest coverAverage
Valuation
Fair value vs priceAverage
EBIT / EV yieldAverage
Profitability
Return on invested capitalGood
Operating marginGood
Gross profitabilityAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 55/100.
Financials
| FY22 | FY23 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $78.7B | $80.0B | $85.2B | $88.8B | $94.2B |
| Operating income | $19.4B | $19.6B | $15.8B | $17.4B | $33.6B |
| Net income | $20.9B | $17.9B | $35.2B | $14.1B | $26.8B |
| Operating cash flow | $23.4B | $21.2B | $22.8B | $24.3B | $24.5B |
| Operating margin | 24.6% | 24.5% | 18.6% | 19.6% | 35.6% |
| Free cash flow | $19.8B | $17.2B | $18.2B | $19.8B | $19.7B |
| Diluted EPS | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bearish
4 bullish · 4 neutral · 8 bearish
Weekly
Neutral
6 bullish · 1 neutral · 5 bearish
Monthly
Strongly bullish
7 bullish · 0 neutral · 1 bearish
Moving averages (daily)
| SMA 10 | 255.9 | Bearish |
| EMA 10 | 256.7 | Bearish |
| SMA 20 | 261.4 | Bearish |
| EMA 20 | 259.7 | Bearish |
| SMA 50 | 264.9 | Bearish |
| EMA 50 | 261.0 | Bearish |
| SMA 100 | 255.4 | Bullish |
| EMA 100 | 255.1 | Bullish |
| SMA 200 | 242.3 | Bullish |
| EMA 200 | 240.3 | Bullish |
Oscillators (daily)
| RSI (14) | 43.83 | Neutral |
| MACD (12, 26) | -3.30 | Bearish |
| Momentum (12) | -3.47 | Bearish |
| Stochastic %K (14) | 38.88 | Neutral |
| Williams %R (14) | -61.12 | Neutral |
| CCI (20) | -59.77 | Neutral |
Pivot points (classic, last session)
S3 250.3 | S2 252.2 | S1 253.9 | Pivot 255.7 | R1 257.4 | R2 259.3 | R3 261.0 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
5.28 USD
Yield on today's price
2.07%
Frequency
Quarterly
Next ex-dividend date
24 Nov 2026
| Ex-dividend date | Amount per share |
|---|---|
| 24 Nov 2026 (upcoming) | 1.3400 |
| 25 Aug 2026 | 1.3400 |
| 26 May 2026 | 1.3400 |
| 24 Feb 2026 | 1.3000 |
| 25 Nov 2025 | 1.3000 |
| 26 Aug 2025 | 1.3000 |
| 27 May 2025 | 1.3000 |
| 18 Feb 2025 | 1.2400 |
| 26 Nov 2024 | 1.2400 |
| 27 Aug 2024 | 1.2400 |
| 20 May 2024 | 1.2400 |
| 16 Feb 2024 | 1.1900 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
JNJ SEC filings
13 Oct 2026
8-KSEC EDGAR
Results of operations
4 Aug 2026
8-KSEC EDGAR
Director or officer change
29 Jul 2026
8-KSEC EDGAR
Regulation FD disclosure
28 Jul 2026
8-KSEC EDGAR
Regulation FD disclosure
23 Jul 2026
10-QSEC EDGAR
Quarterly report
15 Jul 2026
8-KSEC EDGAR
Results of operations
28 Apr 2026
8-KSEC EDGAR
Shareholder vote results
22 Apr 2026
10-QSEC EDGAR
Quarterly report
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.